TELA Bio, Inc. (TELA) Stock Analysis and Metrics

TELA Bio

NASDAQ: TELA

$0.70 ▼ -0.01 (-1.55%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap40.65 Mn

P/E-1.02

P/S0.50

Div. Yield0.00

ROIC (Qtr)-0.10

Total Debt (Qtr)55.87 Mn

Revenue Growth (1y) (Qtr)2.91

Add ratio to table…

About

TELA Bio, Inc. is a commercial-stage medical technology company that develops and sells innovative soft tissue reconstruction solutions. Its products are designed to preserve and restore patient anatomy by combining biologic material derived from ovine rumen with polymer reinforcement. The company focuses on two primary markets: hernia repair and abdominal wall reconstruction, and plastic and reconstructive surgery. In the hernia repair market it offers the OviTex Reinforced Tissue Matrix portfolio which includes configurations for open, laparoscopic and robotic assisted procedures such as OviTex LPR for laparoscopic and robotic assisted use and OviTex IHR for inguinal hernia repair. In the plastic and reconstructive surgery market it offers the OviTex PRS Reinforced Tissue Matrix portfolio with options for short term resorbable, permanent and long term resorbable materials. All products are provided as sterile dry sheets that require brief rehydration before implantation and are intended to reinforce soft tissue where weakness exists.

TELA Bio generates revenue principally from the sale of its OviTex and OviTex PRS reinforced tissue matrices to hospitals and ambulatory surgery centers in the United States, with additional sales in Europe and limited revenue from complementary products such as the LIQUIFIX hernia mesh fixation devices. The company reported revenue of $80.3 million for the year ended December 31, 2025 and $69.3 million for the year ended December 31, 2024 representing a year over year increase of $11.0 million or 16%. The vast majority of revenue to date has been generated from sales of OviTex and OviTex PRS products in the United States with the remainder coming from European sales and other product lines. In September 2023 TELA Bio entered into a distribution agreement with Advanced Medical Solutions Limited to distribute the LIQUIFIX FIX8 and LIQUIFIX Precision hernia mesh fixation devices in the United States and announced the full commercial launch of these devices in March 2024. Earlier the company co developed and commercialized the NIVIS fibrillar collagen pack with Regenity Biosciences and in March 2024 sold its distribution rights to MiMedx Group Inc for an initial $5.0 million payment plus potential future payments ranging from $3.0 million to $7.0 million based on net sales of the product now marketed as HELIOGEN.

Within the hernia repair market TELA Bio competes with established players such as Bard a subsidiary of Becton Dickinson and Company which offers Phasix and Ventralight ST and Allergan an AbbVie subsidiary which markets Strattice. In the plastic and reconstructive surgery arena its rivals include Allergan with AlloDerm MTF Biologics with FlexHD Novadaq with DermACell RTI Surgical with Cortiva Bard with GalaFLEX and Integra Lifesciences with SurgiMend and DuraSorb. The company differentiates itself through its proprietary reinforced tissue matrix technology that interweaves polymer fibers through ovine rumen providing improved handling lower inflammatory response and competitive pricing. Its exclusive supply agreement with Aroa secures a low cost source of biologic material while a broad intellectual property portfolio and clinical data demonstrating low recurrence rates support its market position. Based on the volume weighted average selling price of its OviTex products TELA Bio estimates the annual U. S. total addressable market opportunity for its OviTex portfolio to be approximately $1.8 billion. Based on current sales of biologic matrices in the United States it estimates the annual U. S. current addressable market opportunity for its OviTex PRS products to be approximately $800 million. Clinical evidence from the BRAVO study showed a 24 month recurrence rate of 2.6% for OviTex in primary or recurrent ventral hernias with 38% of patients experiencing surgical site occurrences and 78% of the enrolled cohort classified as high risk for such events. Surgeon satisfaction with the product in the BRAVO study averaged 9.7 out of 10 at 30 days for the minimally invasive cohort and remained consistent over 24 months of follow up. The reinforced tissue matrix design allows for load sharing between biologic material and polymer providing mid term and long term strength while preserving physiologic compliance properties.

TELA Bio serves hospitals ambulatory surgery centers and surgeons who perform soft tissue reconstruction procedures. Its customers also include group purchasing organizations and integrated delivery networks that facilitate broad access to its products. As of December 31, 2025 the company had contracted with three national group purchasing organizations in the United States covering its OviTex and OviTex PRS product lines. In addition to its direct sales force in the United States TELA Bio maintains a small number of sales representatives in the United Kingdom and the European Union and uses independent contractors and distributors in select European countries. The filing does not disclose specific customer names so the base is described by institution type rather than individual entities.

Investment Thesis

▲ Bull case

TELA Bio is positioned to capitalize on structural shifts in the hernia repair market driven by the accelerating adoption of robotic and laparoscopic procedures, which favor its LPR and IHR product lines. Management explicitly noted that surgeons are voting with their preferences for minimally invasive techniques, and TELA’s portfolio is well-aligned with this evolution. The company highlighted that its LPR product is outpacing much of its growth due to compatibility with robotic platforms, and that its inguinal product is robot-compatible as well. This is not a temporary trend but a durable shift in surgical practice, with robotic hernia procedures growing rapidly globally. TELA’s early investment in robot-friendly products gives it a first-mover advantage in capturing share from legacy open-surgery-focused competitors, particularly as hospital systems continue to invest in robotic infrastructure and surgeons gain proficiency. The long-term implication is a sustainable shift toward higher unit volumes with lower ASPs per piece but greater procedural frequency—a dynamic TELA is uniquely structured to benefit from through its product mix and commercial focus on procedural adoption rather than just unit size.
The company’s commercial restructuring has created a high-potential, underappreciated growth engine through its new sales talent profile and depth-of-account strategy. TELA has intentionally shifted recruitment away from legacy soft tissue sales experience toward candidates with high intellect, perseverance, relationship-building skills, and clinical acumen—traits that enable faster mastery of complex products like OviTex. Management emphasized that these new hires, despite being early in tenure (40% of the force joined in the last six months), are already outperforming predecessors and are expected to deliver greater impact at maturity than prior cohorts. This is not merely a headcount increase but a qualitative upgrade in sales effectiveness. Combined with the new compensation plan incentivizing deeper penetration at high-volume institutions—targeting multiple users per site rather than broad geographic coverage—TELA is building stickiness and reducing competitive vulnerability. The strategy transforms transactional sales into entrenched, multi-user relationships that are harder to dislodge by rivals, creating a durable moat around key accounts.
European markets represent a significant, under-leveraged growth driver that management consistently highlighted as stable, tenured, and delivering above plan—yet received less promotional emphasis than U.S. initiatives. TELA reported 17% YoY growth in European sales to $12.1 million in 2025, driven by rapid adoption in the U.K. and Netherlands based on patient preference and product efficacy, not pricing discounts. The company explicitly framed Europe as a “meaningful contributor to growth in the coming years” with a purposeful investment plan to expand into continental Europe. Unlike the U.S., where contracting and rebate complexities create friction, European markets operate more on clinical merit and surgeon preference—playing directly to TELA’s strengths in evidence-based differentiation and tissue integration. With OviTex’s mechanism of action and long-term resorption profile resonating strongly in value-based European systems, and with PRS expansion planned for the region by end of 2026 or early 2027, TELA is poised to replicate its U.S. success in a less complex, more predictable commercial environment. This geographic diversification reduces reliance on U.S. contract execution risks and provides a steady, high-margin growth base.
The upcoming full launch of OviTex LTR (Long-Term Resorbable) in April 2026 presents a hidden catalyst that could meaningfully expand TELA’s addressable market beyond current hernia and PRS indications. Management noted the product has zero permanent polymer, making it ideal for surgeons with concerns about permanent implants—particularly in complex trauma, contaminated fields, or patients undergoing chemotherapy, as illustrated in the patient story shared during the call. This addresses an unmet need in the growing segment of surgeons and patients seeking biologics that fully resorb without leaving foreign material. OviTex LTR is positioned as a direct competitor to biosynthetics like Phasix but with TELA’s proprietary tissue-based technology, potentially offering superior integration and remodeling. Early traction suggests it will be additive to the portfolio with some cannibalization of permanent products—a favorable mix shift toward higher-value, differentiated offerings. Given the rising prevalence of chemotherapy-associated hernia repairs and increasing surgeon aversion to permanent synthetics, OviTex LTR could unlock new clinical indications and hospital formularies where current TELA products face resistance, thereby expanding TAM and driving premium pricing power.

TELA Bio is positioned to capitalize on structural shifts in the hernia repair market driven by the accelerating adoption of robotic and laparoscopic procedures, which favor its LPR and IHR product lines. Management explicitly noted that surgeons are voting with their preferences for minimally invasive techniques, and TELA’s portfolio is well-aligned with this evolution. The company highlighted that its LPR product is outpacing much of its growth due to compatibility with robotic platforms, and that its inguinal product is robot-compatible as well. This is not a temporary trend but a durable shift in surgical practice, with robotic hernia procedures growing rapidly globally. TELA’s early investment in robot-friendly products gives it a first-mover advantage in capturing share from legacy open-surgery-focused competitors, particularly as hospital systems continue to invest in robotic infrastructure and surgeons gain proficiency. The long-term implication is a sustainable shift toward higher unit volumes with lower ASPs per piece but greater procedural frequency—a dynamic TELA is uniquely structured to benefit from through its product mix and commercial focus on procedural adoption rather than just unit size.
The company’s commercial restructuring has created a high-potential, underappreciated growth engine through its new sales talent profile and depth-of-account strategy. TELA has intentionally shifted recruitment away from legacy soft tissue sales experience toward candidates with high intellect, perseverance, relationship-building skills, and clinical acumen—traits that enable faster mastery of complex products like OviTex. Management emphasized that these new hires, despite being early in tenure (40% of the force joined in the last six months), are already outperforming predecessors and are expected to deliver greater impact at maturity than prior cohorts. This is not merely a headcount increase but a qualitative upgrade in sales effectiveness. Combined with the new compensation plan incentivizing deeper penetration at high-volume institutions—targeting multiple users per site rather than broad geographic coverage—TELA is building stickiness and reducing competitive vulnerability. The strategy transforms transactional sales into entrenched, multi-user relationships that are harder to dislodge by rivals, creating a durable moat around key accounts.
European markets represent a significant, under-leveraged growth driver that management consistently highlighted as stable, tenured, and delivering above plan—yet received less promotional emphasis than U.S. initiatives. TELA reported 17% YoY growth in European sales to $12.1 million in 2025, driven by rapid adoption in the U.K. and Netherlands based on patient preference and product efficacy, not pricing discounts. The company explicitly framed Europe as a “meaningful contributor to growth in the coming years” with a purposeful investment plan to expand into continental Europe. Unlike the U.S., where contracting and rebate complexities create friction, European markets operate more on clinical merit and surgeon preference—playing directly to TELA’s strengths in evidence-based differentiation and tissue integration. With OviTex’s mechanism of action and long-term resorption profile resonating strongly in value-based European systems, and with PRS expansion planned for the region by end of 2026 or early 2027, TELA is poised to replicate its U.S. success in a less complex, more predictable commercial environment. This geographic diversification reduces reliance on U.S. contract execution risks and provides a steady, high-margin growth base.
The upcoming full launch of OviTex LTR (Long-Term Resorbable) in April 2026 presents a hidden catalyst that could meaningfully expand TELA’s addressable market beyond current hernia and PRS indications. Management noted the product has zero permanent polymer, making it ideal for surgeons with concerns about permanent implants—particularly in complex trauma, contaminated fields, or patients undergoing chemotherapy, as illustrated in the patient story shared during the call. This addresses an unmet need in the growing segment of surgeons and patients seeking biologics that fully resorb without leaving foreign material. OviTex LTR is positioned as a direct competitor to biosynthetics like Phasix but with TELA’s proprietary tissue-based technology, potentially offering superior integration and remodeling. Early traction suggests it will be additive to the portfolio with some cannibalization of permanent products—a favorable mix shift toward higher-value, differentiated offerings. Given the rising prevalence of chemotherapy-associated hernia repairs and increasing surgeon aversion to permanent synthetics, OviTex LTR could unlock new clinical indications and hospital formularies where current TELA products face resistance, thereby expanding TAM and driving premium pricing power.

▼ Bear case

TELA Bio’s 2026 revenue guidance of at least 8% YoY growth appears overly optimistic given the significant execution risks embedded in its commercial restructuring, particularly the unproven scalability of its new sales model. While management highlighted that 40% of the sales force joined in the last six months and are ramping toward productivity, they acknowledged that territory manager breakeven remains six to nine months and that new reps require clinical education to reach full effectiveness. The company is betting that these high-intellect, relationship-focused hires will ultimately outperform legacy reps—but this remains an untested hypothesis at scale. There is no evidence in the transcript that the new profile has yet demonstrated sustained, measurable superiority in quota attainment or territory development beyond early onboarding optimism. If the ramp takes longer than expected or if the new reps fail to convert clinical acumen into consistent sales execution, the expected inflection in the second half of 2026 may not materialize, leaving the company dependent on its tenured rep base (only 35% of the force) to carry growth—an unsustainable reliance given their limited scale and potential fatigue from ongoing organizational change.
The company’s strategic shift toward deeper account penetration—targeting multiple users per site instead of broad geographic coverage—introduces material execution risk that could undermine near-term revenue stability. Management admitted this shift requires abandoning or de-emphasizing lower-volume, peripheral accounts (the “hinterlands”) to concentrate density in high-population areas. While this may improve long-term stickiness, it creates immediate vulnerability: if reps fail to successfully engage additional surgeons within target accounts due to entrenched competitor relationships, lack of clinical bandwidth, or insufficient support from hospital administration, TELA risks losing coverage in both legacy and new territories without gaining sufficient depth to compensate. The transcript reveals that the company is still in the early phases of implementing this model, with Jeffrey noting they are “setting ourselves up to do” this strategy—not that it is already working. Without proven success in multi-user engagement, the approach could result in net territory attrition and reduced overall reach, especially during the Q1 transition period where weather and insurance reset already impacted volumes.
TELA’s dependence on European growth as a structural cushion masks underlying fragility in its U.S. commercial engine, where growth is increasingly contingent on complex contract execution—a process management itself described as fraught with timing variability and administrative complexity. Antony explicitly cited contract conversion and execution as a key factor of safety in their guidance, noting that GPO contracts vary widely in implementation due to market share clauses, bundling, and rebate structures, and that translating signed agreements into actual patient usage requires navigating hospital-specific admin processes. Jim Hagen confirmed that 2026 is an “execution year” focused on moving signed site-level agreements through hospital processes to generate revenue—a tacit admission that past success in securing agreements has not yet translated into proportional revenue. If the company continues to struggle with contract execution—as implied by the need to shift focus from contracting to execution—the anticipated U.S. growth may be delayed or diminished, leaving TELA over-reliant on Europe, which, while growing, remains a small fraction of total revenue (15% in 2025) and cannot alone offset U.S. shortfalls.
The long-term growth narrative hinges on unproven assumptions about procedural mix shifts toward smaller, robotically assisted hernia repairs—particularly inguinal and hiatal—without clear evidence that TELA can monetize these shifts effectively. Management acknowledged that the shift from ventral (70%) to ventral (50%) and inguinal (10–12% to 25%) is altering ASPs, with volume moving to lower-priced pieces like 1s, 2s, and Core. While they argue this will be offset by higher unit volumes, there is no discussion of pricing power or ASP stabilization in these newer segments. Inguinal procedures, though numerous (~1M/year), are highly price-sensitive and dominated by low-cost synthetic meshes; TELA’s premium biologic faces stiff competition unless it demonstrates clear clinical superiority in robotic-assisted inguinal repair—a claim not substantiated in the transcript. Furthermore, the company’s optimism about LiquiFix as a gateway to hernia surgeons relies on a partnership with AMS, but no data was provided on adoption rates or conversion lift. If the mix shift continues without a corresponding increase in unit volume or ASP resilience, TELA could face persistent top-line pressure despite procedural growth, undermining its long-term double-digit growth aspiration.

TELA Bio’s 2026 revenue guidance of at least 8% YoY growth appears overly optimistic given the significant execution risks embedded in its commercial restructuring, particularly the unproven scalability of its new sales model. While management highlighted that 40% of the sales force joined in the last six months and are ramping toward productivity, they acknowledged that territory manager breakeven remains six to nine months and that new reps require clinical education to reach full effectiveness. The company is betting that these high-intellect, relationship-focused hires will ultimately outperform legacy reps—but this remains an untested hypothesis at scale. There is no evidence in the transcript that the new profile has yet demonstrated sustained, measurable superiority in quota attainment or territory development beyond early onboarding optimism. If the ramp takes longer than expected or if the new reps fail to convert clinical acumen into consistent sales execution, the expected inflection in the second half of 2026 may not materialize, leaving the company dependent on its tenured rep base (only 35% of the force) to carry growth—an unsustainable reliance given their limited scale and potential fatigue from ongoing organizational change.
The company’s strategic shift toward deeper account penetration—targeting multiple users per site instead of broad geographic coverage—introduces material execution risk that could undermine near-term revenue stability. Management admitted this shift requires abandoning or de-emphasizing lower-volume, peripheral accounts (the “hinterlands”) to concentrate density in high-population areas. While this may improve long-term stickiness, it creates immediate vulnerability: if reps fail to successfully engage additional surgeons within target accounts due to entrenched competitor relationships, lack of clinical bandwidth, or insufficient support from hospital administration, TELA risks losing coverage in both legacy and new territories without gaining sufficient depth to compensate. The transcript reveals that the company is still in the early phases of implementing this model, with Jeffrey noting they are “setting ourselves up to do” this strategy—not that it is already working. Without proven success in multi-user engagement, the approach could result in net territory attrition and reduced overall reach, especially during the Q1 transition period where weather and insurance reset already impacted volumes.
TELA’s dependence on European growth as a structural cushion masks underlying fragility in its U.S. commercial engine, where growth is increasingly contingent on complex contract execution—a process management itself described as fraught with timing variability and administrative complexity. Antony explicitly cited contract conversion and execution as a key factor of safety in their guidance, noting that GPO contracts vary widely in implementation due to market share clauses, bundling, and rebate structures, and that translating signed agreements into actual patient usage requires navigating hospital-specific admin processes. Jim Hagen confirmed that 2026 is an “execution year” focused on moving signed site-level agreements through hospital processes to generate revenue—a tacit admission that past success in securing agreements has not yet translated into proportional revenue. If the company continues to struggle with contract execution—as implied by the need to shift focus from contracting to execution—the anticipated U.S. growth may be delayed or diminished, leaving TELA over-reliant on Europe, which, while growing, remains a small fraction of total revenue (15% in 2025) and cannot alone offset U.S. shortfalls.
The long-term growth narrative hinges on unproven assumptions about procedural mix shifts toward smaller, robotically assisted hernia repairs—particularly inguinal and hiatal—without clear evidence that TELA can monetize these shifts effectively. Management acknowledged that the shift from ventral (70%) to ventral (50%) and inguinal (10–12% to 25%) is altering ASPs, with volume moving to lower-priced pieces like 1s, 2s, and Core. While they argue this will be offset by higher unit volumes, there is no discussion of pricing power or ASP stabilization in these newer segments. Inguinal procedures, though numerous (~1M/year), are highly price-sensitive and dominated by low-cost synthetic meshes; TELA’s premium biologic faces stiff competition unless it demonstrates clear clinical superiority in robotic-assisted inguinal repair—a claim not substantiated in the transcript. Furthermore, the company’s optimism about LiquiFix as a gateway to hernia surgeons relies on a partnership with AMS, but no data was provided on adoption rates or conversion lift. If the mix shift continues without a corresponding increase in unit volume or ASP resilience, TELA could face persistent top-line pressure despite procedural growth, undermining its long-term double-digit growth aspiration.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Customer Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Customer Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password